沙利度胺联合强的松治疗重度溃疡性结肠炎患者的临床研究

Clinical Study on Thalidomide Combined with Prednisone in the Treatment of Patients with Severe Ulcerative Colitis

目的探讨沙利度胺联合强的松治疗重度溃疡性结肠炎(UC)患者的临床效果。方法选取2021年1月至2022年12月我院收治的120例重度UC患者,随机分为两组各60例。参照组予以强的松治疗,研究组在参照组基础上予以沙利度胺治疗。比较两组的治疗效果、炎性因子水平以及不良反应。结果研究组的治疗总有效率为83.33%,明显高于参照组的58.33%(P<0.05)。治疗后,研究组的血清IL-2、IFN-γ水平均明显低于参照组,IL-4、IL-10水平均明显高于参照组(P<0.05)。研究组的不良反应总发生率(15.00%)与参照组(13.33%)相比,差异无统计学意义(P>0.05)。结论沙利度胺联合强的松治疗重度UC的效果显著,可明显减轻患者炎性反应,安全性高。

Objective To explore the clinical effect of thalidomide combined with prednisone in the treatment of patients with severe ulcerative colitis(UC).Methods A total of 120 patients with severe UC admitted to our hospital from January 2021 to December 2022 were selected and randomly divided into two groups,with 60 cases in each group.The reference group was treated with prednisone,and the study group was treated with thalidomide on the basis of the reference group.The therapeutic effect,inflammatory factor levels and adverse reactions were compared between the two groups.Results The total effective rate of treatment in the study group was 83.33%,significantly higher than 58.33%in the reference group(P<0.05).After treatment,the levels of serum IL-2 and IFN-γin the study group were significantly lower than those in the reference group,and the levels of IL-4 and IL-10 were significantly higher than those in the reference group(P<0.05).No significant difference was found in the total incidence of adverse reactions between the study group and the reference group(15.00%vs.13.33%,P>0.05).Conclusions Thalidomide combined with prednisone in the treatment of severe UC has significant effect and high safety,which can obviously relieve patients'inflammatory reaction.